piracetam has been researched along with Pregnancy in 69 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this review was to assess the effects of piracetam for suspected fetal distress in labour on method of delivery and perinatal morbidity." | 8.88 | Piracetam for fetal distress in labour. ( Hofmeyr, GJ; Kulier, R, 2012) |
| "If levetiracetam is used during pregnancy, women should receive adequate amounts of folic acid (0." | 8.85 | Levetiracetam use in pregnancy. ( Forinash, AB; Longo, B; Murphy, JA, 2009) |
| "There is not enough evidence to evaluate the use of piracetam for fetal distress in labour." | 8.81 | Piracetam for fetal distress in labour. ( Hofmeyr, GJ; Kulier, R, 2002) |
| "The objective of this review was to assess the effects of piracetam for suspected fetal distress in labour on method of delivery and perinatal morbidity." | 8.80 | Piracetam for fetal distress in labour. ( Hofmeyr, GJ; Kulier, R, 2000) |
| " Levetiracetam (LEV) is considered to be safe during pregnancy because of its low teratogenic potential and lack of drug-drug interaction with other antiseizure medications (ASMs)." | 8.31 | Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy. ( Edens, M; Schelhaas, M; Ter Horst, P; Touw, D; Wammes-Van Der Heijden, E; Wegner, I, 2023) |
| "This study, in a meaningful number of exposed pregnancies, confirms a low risk for MCM with levetiracetam monotherapy use in pregnancy." | 7.79 | Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. ( Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Liggan, B; Mawhinney, E; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2013) |
| "Variations in the plasma concentration of levetiracetam during pregnancy and postpartum were prospectively monitored in five women to investigate their potential implications in epilepsy management and child outcome." | 7.75 | Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. ( Cid, AO; Juste, AO; López-Fraile, IP; Modrego, PJ, 2009) |
| "To study pharmacokinetics of levetiracetam (LEV) during pregnancy, delivery, lactation, and in the neonatal period." | 7.74 | Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. ( Ben-Menachem, E; Danielsson, B; Johansson, R; Källén, K; Luef, G; Ohman, I; Palm, R; Söderfeldt, B; Tomson, T, 2007) |
| "Levetiracetam (LEV) has been considered to undergo no significant change in bioavailability during pregnancy; however, it was recently demonstrated to display modifications leading to a drop in its serum level." | 7.74 | Impending status epilepticus and anxiety in a pregnant woman treated with levetiracetam. ( Hubschmid, M; Michel, P; Novy, J; Rossetti, AO, 2008) |
| "To investigate changes in levetiracetam (LEV) serum concentration/dose ratio (C/D-ratio) in relation to pregnancy." | 7.74 | Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. ( Brodtkorb, E; Helde, G; Nakken, KO; Reimers, A; Westin, AA, 2008) |
| "It is not known whether the antiepileptic drug (AED) levetiracetam can be used safely in human pregnancy." | 7.73 | Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. ( Craig, J; Guthrie, E; Hunt, S; Irwin, B; Morrison, PJ; Morrow, J; Parsons, L; Robertson, I; Russell, A; Waddell, R, 2006) |
| "Preliminary data in pregnancy are promising, but more data are needed on the impact of levetiracetam on the developing fetus and pharmacokinetic alterations caused in pregnancy." | 6.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 5.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| "LCM and LEV were both effective against seizures induced by PTZ." | 5.46 | Treatment with lacosamide impedes generalized seizures in a rodent model of cortical dysplasia. ( Alexopoulos, AV; Gonzalez-Martinez, J; Najm, IM; Nemes, AD; O'Dwyer, R; Ying, Z, 2017) |
| "Lacosamide level in milk was low, resulting in an estimated relative infant dose of 1." | 5.42 | Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy. ( Ketola, RA; Malm, H; Ruuskanen, JO; Timonen, S; Ylikotila, P, 2015) |
| "The objective of this review was to assess the effects of piracetam for suspected fetal distress in labour on method of delivery and perinatal morbidity." | 4.88 | Piracetam for fetal distress in labour. ( Hofmeyr, GJ; Kulier, R, 2012) |
| "If levetiracetam is used during pregnancy, women should receive adequate amounts of folic acid (0." | 4.85 | Levetiracetam use in pregnancy. ( Forinash, AB; Longo, B; Murphy, JA, 2009) |
| "There is not enough evidence to evaluate the use of piracetam for fetal distress in labour." | 4.81 | Piracetam for fetal distress in labour. ( Hofmeyr, GJ; Kulier, R, 2002) |
| "The objective of this review was to assess the effects of piracetam for suspected fetal distress in labour on method of delivery and perinatal morbidity." | 4.80 | Piracetam for fetal distress in labour. ( Hofmeyr, GJ; Kulier, R, 2000) |
| " Levetiracetam (LEV) is considered to be safe during pregnancy because of its low teratogenic potential and lack of drug-drug interaction with other antiseizure medications (ASMs)." | 4.31 | Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy. ( Edens, M; Schelhaas, M; Ter Horst, P; Touw, D; Wammes-Van Der Heijden, E; Wegner, I, 2023) |
| "Levetiracetam is a new generation antiepileptic drug used in treatment of patients with epilepsy and has adverse effects on different tissues." | 3.85 | Evaluation of apoptotic cell death on liver and kidney tissues following administration of levetiracetam during prenatal period. ( Ayas, B; Elbistan, M; Guvenc, T; Kara, N; Tekcan, A; Tural, S, 2017) |
| " Children exposed to monotherapy levetiracetam (n = 42), topiramate (n = 27), or valproate (n = 47) and a group of children born to women who had untreated epilepsy (n = 55) were enrolled retrospectively from the UK Epilepsy and Pregnancy Register." | 3.83 | Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. ( Baker, GA; Bromley, RL; Calderbank, R; Cheyne, CP; Clayton-Smith, J; García-Fiñana, M; Irwin, B; Morrow, JI; Rooney, C; Shallcross, R; Trayner, P, 2016) |
| "To assess the effectiveness of the newer antiepileptic drugs (AEDs)-in particular lamotrigine, topiramate, and levetiracetam-in controlling epileptic seizures in pregnant women." | 3.80 | The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy. ( Eadie, M; Graham, J; Lander, C; O'Brien, T; Vajda, FJ, 2014) |
| "Evidence from this and other studies suggests that lamotrigine and levetiracetam have low risk for teratogenesis, but that topiramate exposure early in pregnancy may be associated with dose-related anatomical teratogenesis, as valproate is already known to be." | 3.80 | The teratogenicity of the newer antiepileptic drugs - an update. ( Eadie, MJ; Graham, J; Lander, CM; O'Brien, TJ; Vajda, FJ, 2014) |
| "To compare the cognitive and language development of children born to women with epilepsy (WWE) exposed in utero to levetiracetam (LEV) or sodium valproate (VPA) and control children born to women without epilepsy not taking medication during pregnancy." | 3.80 | In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. ( Baker, GA; Bromley, RL; Cheyne, CP; García-Fiñana, M; Irwin, B; Morrow, J; Shallcross, R, 2014) |
| "This study, in a meaningful number of exposed pregnancies, confirms a low risk for MCM with levetiracetam monotherapy use in pregnancy." | 3.79 | Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. ( Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Liggan, B; Mawhinney, E; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2013) |
| "Children born to women with epilepsy (WWE), exposed in utero to levetiracetam (LEV, n = 51), were assessed for early cognitive development and compared to children exposed to sodium valproate in utero (VPA, n = 44) and a group of children representative of the general population (n = 97)." | 3.77 | Child development following in utero exposure: levetiracetam vs sodium valproate. ( Baker, GA; Bonnett, LJ; Bromley, RL; Irwin, B; Morrow, J; Shallcross, R, 2011) |
| "The effect on clearance of levetiracetam (LEV) was estimated in women with epilepsy of childbearing potential using oral contraceptives (OCs)." | 3.77 | No effect of oral contraceptives on the metabolism of levetiracetam. ( Christensen, J; Sabers, A, 2011) |
| "We showed that levetiracetam had only a transient impact on reflex maturation and no impact on physical and cognitive function in offspring of rats exposed to the drug during pregnancy." | 3.76 | Effect of prenatal levetiracetam exposure on motor and cognitive functions of rat offspring. ( Bas, DB; Bilge, S; Bozkurt, A; Ciftcioglu, E; Ilkaya, F; Ozyurek, H, 2010) |
| "Variations in the plasma concentration of levetiracetam during pregnancy and postpartum were prospectively monitored in five women to investigate their potential implications in epilepsy management and child outcome." | 3.75 | Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. ( Cid, AO; Juste, AO; López-Fraile, IP; Modrego, PJ, 2009) |
| "To study pharmacokinetics of levetiracetam (LEV) during pregnancy, delivery, lactation, and in the neonatal period." | 3.74 | Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. ( Ben-Menachem, E; Danielsson, B; Johansson, R; Källén, K; Luef, G; Ohman, I; Palm, R; Söderfeldt, B; Tomson, T, 2007) |
| "To investigate changes in levetiracetam (LEV) serum concentration/dose ratio (C/D-ratio) in relation to pregnancy." | 3.74 | Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. ( Brodtkorb, E; Helde, G; Nakken, KO; Reimers, A; Westin, AA, 2008) |
| "Levetiracetam (LEV) has been considered to undergo no significant change in bioavailability during pregnancy; however, it was recently demonstrated to display modifications leading to a drop in its serum level." | 3.74 | Impending status epilepticus and anxiety in a pregnant woman treated with levetiracetam. ( Hubschmid, M; Michel, P; Novy, J; Rossetti, AO, 2008) |
| "It is not known whether the antiepileptic drug (AED) levetiracetam can be used safely in human pregnancy." | 3.73 | Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. ( Craig, J; Guthrie, E; Hunt, S; Irwin, B; Morrison, PJ; Morrow, J; Parsons, L; Robertson, I; Russell, A; Waddell, R, 2006) |
| "Piracetam (PIR) and dimethylaminoethanol (DMAE) were tested with respect to their ability to prevent changes of the locomotor behaviour and of the dopamine release from striatum slices after an intermittent postnatal hypoxia in the rat (2nd-10th day of postnatal life)." | 3.67 | Effects of nootropic drugs on some behavioural and biochemical changes after early postnatal hypoxia in the rat. ( Fischer, HD; Gramatté, T; Schmidt, J; Wustmann, C, 1986) |
| " Because of its large between-subject variability, several population pharmacokinetic studies have been performed to identify its pharmacokinetic covariates, and thus facilitate individualised therapy." | 2.72 | Population Pharmacokinetics of Levetiracetam: A Systematic Review. ( Jiao, Z; Li, ZR; Wang, CY; Zhu, X, 2021) |
| "Piracetam was applicated to 17 patients in the beginning of cervix dilatation, whereas the other patients got Laevulose as a placebo infusion." | 2.65 | [The protective effect of piracetam during delivery]. ( Grosspietzsch, R; Klink, F; Oberheuser, F; von Klitzing, L, 1979) |
| "Levetiracetam was the drug of choice in treating patients with hepatic failure, or who have undergone organ transplantation." | 2.55 | Epilepsy treatment in adults and adolescents: Expert opinion, 2016. ( Chimato, N; Frank, RD; Karceski, SC; Shih, JJ; Vargas, E; Whitlock, JB, 2017) |
| "The current evidence suggests that the overall risk of major malformation after first trimester exposure to Levetiracetam is within the population baseline risk of 1-3%, with no apparent adverse effects on long term child development." | 2.50 | The fetal safety of Levetiracetam: a systematic review. ( Chaudhry, SA; Jong, G; Koren, G, 2014) |
| "Juvenile myoclonic epilepsy is a common idiopathic generalized epileptic syndrome that includes generalized myoclonic seizures and commonly generalized tonic-clonic and generalized absence seizures." | 2.45 | The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? ( Abou-Khalil, B; Montouris, G, 2009) |
| "Levetiracetam is an antiepileptic drug approved for use as an adjunct agent in partial-onset seizures in adults and children aged > or = 4 years." | 2.44 | The safety of levetiracetam. ( Safdieh, JE; Sirsi, D, 2007) |
| "Preliminary data in pregnancy are promising, but more data are needed on the impact of levetiracetam on the developing fetus and pharmacokinetic alterations caused in pregnancy." | 2.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "Each antiepileptic drug has a characteristic pharmacokinetic profile, and the unique properties of each must be considered when selecting the optimal agent for a particular patient." | 2.41 | Pharmacokinetic considerations in prescribing antiepileptic drugs. ( Faught, E, 2001) |
| "Levetiracetam is a Pregnancy Category C drug." | 2.41 | Safety profile of levetiracetam. ( Harden, C, 2001) |
| " The non-habitual seizures completely disappeared, and the frequency of the habitual seizures improved to the baseline level after the LEV dosage was reduced." | 1.72 | Seizure Deterioration with Increased Levetiracetam Blood Concentration during the Postpartum Period in Refractory Temporal Lobe Epilepsy. ( Aoki, S; Iida, K; Kikumoto, M; Maruyama, H; Neshige, S; Shishido, T; Ueno, H, 2022) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 1.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| "LCM and LEV were both effective against seizures induced by PTZ." | 1.46 | Treatment with lacosamide impedes generalized seizures in a rodent model of cortical dysplasia. ( Alexopoulos, AV; Gonzalez-Martinez, J; Najm, IM; Nemes, AD; O'Dwyer, R; Ying, Z, 2017) |
| "Lacosamide level in milk was low, resulting in an estimated relative infant dose of 1." | 1.42 | Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy. ( Ketola, RA; Malm, H; Ruuskanen, JO; Timonen, S; Ylikotila, P, 2015) |
| " An intensive pharmacokinetic study was performed from immediately before to 11 hours after the morning LVT dose administration and suggested that the patient was not adequately exposed to the drug during the night." | 1.42 | Increased levetiracetam clearance and breakthrough seizure in a pregnant patient successfully handled by intensive therapeutic drug monitoring. ( Cappellari, AM; Cattaneo, D; Clementi, E; Kustermann, A, 2015) |
| " Pharmacokinetic changes associated with pregnancy may increase apparent clearance of extended-release formulations of levetiracetam, leading to periods of subtherapeutic blood or central nervous system concentrations." | 1.40 | Increased levetiracetam clearance associated with a breakthrough seizure in a pregnant patient receiving once/day extended-release levetiracetam. ( Garrity, LC; Standridge, SM; Turner, M, 2014) |
| "Cerebral venous thrombosis is a rare entity in pregnancy and the postpartum period, with an incidence of 1:10,000 to 1:25,000." | 1.37 | Postpartum cerebral venous thrombosis. ( McCaulley, JA; Pates, JA, 2011) |
| "Brain abscess is a rare but life-threatening complication of pregnancy." | 1.37 | Pregnancy complicated by recurrent brain abscess after extraction of an infected tooth. ( Awonuga, AO; Hobson, DTG; Imudia, AN; Soto, E, 2011) |
| "Aniracetam was administered to 1-month-old rats, demonstrating a prolonged (2 months) therapeutic effect, observed in rats aged 3 months." | 1.31 | Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance? ( Vaglenova, J; Vesselinov Petkov, V, 2001) |
| "PIRACETAM was administered intravenously to 43 patients in a dosage 2 g, 4 g and 6 g." | 1.26 | [Pharmacokinetic of piracetam during labour influence to acid-base-status in maternal and fetal blood (author's transl)]. ( Cornely, M; Henkel, E; Künzel, W; Zimmermann, P, 1977) |
| "Piracetam was tolerated without side-effects and injected in the maternal cubital vein." | 1.26 | [Pharmacokinetics of piracetam during delivery]. ( Cornely, M; Henkel, E; Trapp, H, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (17.39) | 18.7374 |
| 1990's | 3 (4.35) | 18.2507 |
| 2000's | 20 (28.99) | 29.6817 |
| 2010's | 31 (44.93) | 24.3611 |
| 2020's | 3 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Kikumoto, M | 1 |
| Neshige, S | 1 |
| Shishido, T | 1 |
| Ueno, H | 1 |
| Aoki, S | 1 |
| Iida, K | 1 |
| Maruyama, H | 1 |
| Schelhaas, M | 1 |
| Wegner, I | 1 |
| Edens, M | 1 |
| Wammes-Van Der Heijden, E | 1 |
| Touw, D | 1 |
| Ter Horst, P | 1 |
| Li, ZR | 1 |
| Wang, CY | 1 |
| Zhu, X | 1 |
| Jiao, Z | 1 |
| Nemes, AD | 1 |
| O'Dwyer, R | 1 |
| Najm, IM | 1 |
| Ying, Z | 1 |
| Gonzalez-Martinez, J | 1 |
| Alexopoulos, AV | 1 |
| Lee, SH | 1 |
| Kang, JW | 1 |
| Lin, T | 1 |
| Lee, JE | 1 |
| Jin, DI | 1 |
| Klein, P | 1 |
| Mathews, GC | 1 |
| Shallcross, R | 3 |
| Bromley, RL | 3 |
| Cheyne, CP | 2 |
| García-Fiñana, M | 2 |
| Irwin, B | 6 |
| Morrow, J | 5 |
| Baker, GA | 3 |
| Chaudhry, SA | 1 |
| Jong, G | 1 |
| Koren, G | 1 |
| Garrity, LC | 1 |
| Turner, M | 1 |
| Standridge, SM | 1 |
| Vajda, FJ | 3 |
| O'Brien, T | 1 |
| Lander, C | 1 |
| Graham, J | 4 |
| Eadie, M | 2 |
| O'Brien, TJ | 3 |
| Lander, CM | 3 |
| Eadie, MJ | 2 |
| Cappellari, AM | 1 |
| Cattaneo, D | 1 |
| Clementi, E | 1 |
| Kustermann, A | 1 |
| Ylikotila, P | 1 |
| Ketola, RA | 1 |
| Timonen, S | 1 |
| Malm, H | 1 |
| Ruuskanen, JO | 1 |
| Janszky, J | 1 |
| Miyazaki, I | 1 |
| Murakami, S | 1 |
| Torigoe, N | 1 |
| Kitamura, Y | 1 |
| Asanuma, M | 1 |
| Vajda, FJE | 1 |
| Vanya, M | 1 |
| Devosa, I | 1 |
| Szok, D | 1 |
| Bártfai, G | 1 |
| Tekcan, A | 1 |
| Tural, S | 1 |
| Elbistan, M | 1 |
| Guvenc, T | 1 |
| Ayas, B | 1 |
| Kara, N | 1 |
| Martinez Ferri, M | 1 |
| Peña Mayor, P | 1 |
| Perez López-Fraile, I | 1 |
| Escartin Siquier, A | 1 |
| Martin Moro, M | 1 |
| Forcadas Berdusan, M | 1 |
| Calderbank, R | 1 |
| Rooney, C | 1 |
| Trayner, P | 1 |
| Clayton-Smith, J | 1 |
| Morrow, JI | 1 |
| Shih, JJ | 1 |
| Whitlock, JB | 1 |
| Chimato, N | 1 |
| Vargas, E | 1 |
| Karceski, SC | 1 |
| Frank, RD | 1 |
| Novy, J | 1 |
| Hubschmid, M | 1 |
| Michel, P | 1 |
| Rossetti, AO | 1 |
| López-Fraile, IP | 1 |
| Cid, AO | 1 |
| Juste, AO | 1 |
| Modrego, PJ | 1 |
| Ozyurek, H | 1 |
| Bozkurt, A | 1 |
| Bilge, S | 1 |
| Ciftcioglu, E | 1 |
| Ilkaya, F | 1 |
| Bas, DB | 1 |
| Longo, B | 1 |
| Forinash, AB | 1 |
| Murphy, JA | 1 |
| Montouris, G | 1 |
| Abou-Khalil, B | 1 |
| Ahishali, B | 1 |
| Kaya, M | 1 |
| Orhan, N | 1 |
| Arican, N | 1 |
| Ekizoglu, O | 1 |
| Elmas, I | 1 |
| Kucuk, M | 1 |
| Kemikler, G | 1 |
| Kalayci, R | 1 |
| Gurses, C | 1 |
| Bonnett, LJ | 1 |
| Iniesta, I | 1 |
| Sabers, A | 1 |
| Christensen, J | 1 |
| McCaulley, JA | 1 |
| Pates, JA | 1 |
| Hobson, DTG | 1 |
| Imudia, AN | 1 |
| Soto, E | 1 |
| Awonuga, AO | 1 |
| Roten, A | 1 |
| Sun, LQ | 1 |
| Slivka, AP | 1 |
| Hoeritzauer, I | 1 |
| Mawhinney, E | 2 |
| Hunt, SJ | 2 |
| Craig, J | 3 |
| Hofmeyr, GJ | 3 |
| Kulier, R | 3 |
| Terada, K | 1 |
| Inoue, Y | 1 |
| Russell, A | 2 |
| Smithson, WH | 1 |
| Parsons, L | 2 |
| Morrison, PJ | 2 |
| Liggan, B | 1 |
| Delanty, N | 1 |
| Long, L | 1 |
| Isoherranen, N | 1 |
| Spiegelstein, O | 1 |
| Bialer, M | 1 |
| Zhang, J | 1 |
| Merriweather, M | 1 |
| Yagen, B | 1 |
| Roeder, M | 1 |
| Triplett, AA | 1 |
| Schurig, V | 1 |
| Finnell, RH | 1 |
| Briggs, DE | 1 |
| French, JA | 1 |
| Johannessen, SI | 1 |
| Helde, G | 2 |
| Brodtkorb, E | 2 |
| Allegaert, K | 1 |
| Lewi, L | 1 |
| Naulaers, G | 1 |
| Lagae, L | 1 |
| Hunt, S | 1 |
| Guthrie, E | 1 |
| Robertson, I | 1 |
| Waddell, R | 1 |
| Tomson, T | 1 |
| Palm, R | 1 |
| Källén, K | 1 |
| Ben-Menachem, E | 1 |
| Söderfeldt, B | 1 |
| Danielsson, B | 1 |
| Johansson, R | 1 |
| Luef, G | 1 |
| Ohman, I | 1 |
| Sirsi, D | 1 |
| Safdieh, JE | 1 |
| Manent, JB | 1 |
| Jorquera, I | 1 |
| Franco, V | 1 |
| Ben-Ari, Y | 1 |
| Perucca, E | 1 |
| Represa, A | 1 |
| Westin, AA | 1 |
| Reimers, A | 1 |
| Nakken, KO | 1 |
| Murphy, R | 1 |
| Daugherty, J | 1 |
| Houry, D | 1 |
| Medek, A | 2 |
| Huaman, EJ | 1 |
| Hassoun, R | 1 |
| Itahashi, CM | 1 |
| Pereda, GJ | 1 |
| Mejia, MA | 1 |
| Lun, A | 1 |
| Fischer, HD | 2 |
| Wustmann, C | 2 |
| Pohle, R | 1 |
| Moller, R | 1 |
| Gross, J | 1 |
| Schmidt, J | 2 |
| Turova, NF | 1 |
| Ermolina, LA | 1 |
| Baryshnikov, VA | 1 |
| Kopaladze, RA | 1 |
| Aziavchik, AV | 1 |
| Klink, F | 2 |
| von Klitzing, L | 2 |
| Grosspietzsch, R | 2 |
| Oberheuser, F | 2 |
| Elera, JH | 1 |
| Sánchez, PM | 1 |
| Garay, JP | 1 |
| Trofimov, SS | 3 |
| Ostrovskaia, RU | 3 |
| Kravchenko, EV | 2 |
| Smol'nikova, NM | 2 |
| Bondarenko, NA | 1 |
| Kutepova, OA | 1 |
| Nemova, EP | 2 |
| Voronina, TA | 2 |
| Chepkova, AN | 1 |
| Smoĺnikova, NI | 1 |
| Gudasheva, TA | 1 |
| Vaglenova, J | 1 |
| Vesselinov Petkov, V | 1 |
| Faught, E | 1 |
| Harden, C | 1 |
| Cornely, M | 2 |
| Henkel, E | 2 |
| Künzel, W | 1 |
| Zimmermann, P | 1 |
| Clemens, JA | 1 |
| Fuller, RW | 1 |
| Trapp, H | 1 |
| Gramatté, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Levetiracetam Treatment of Neonatal Seizures: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Oral Levetiracetam as First Line Treatment for Neonatal Seizures in China[NCT02550028] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2015-09-01 | Terminated (stopped due to The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.) | ||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Study of Maternal Pharmacokinetic and Placental Transfer of Levetiracetam[NCT04117425] | 50 participants (Anticipated) | Interventional | 2022-04-20 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for piracetam and Pregnancy
| Article | Year |
|---|---|
Population Pharmacokinetics of Levetiracetam: A Systematic Review.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Female; Humans; Infant, Newborn; Levetiracetam; Phenyt | 2021 |
The fetal safety of Levetiracetam: a systematic review.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Female; Fetal Diseases; Fetus; Humans; Leveti | 2014 |
Is carbamazepine a human teratogen?
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Carbamazepine; Epilepsy; Female; Fet | 2016 |
[Preconceptional and perinatal challenges of pregnancy in women with epilepsy].
Topics: Adult; Amines; Anticonvulsants; Benzodiazepines; Carbamazepine; Cyclohexanecarboxylic Acids; Epileps | 2016 |
Epilepsy treatment in adults and adolescents: Expert opinion, 2016.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Depression; Double-Blind Method; Dru | 2017 |
Levetiracetam use in pregnancy.
Topics: Anticonvulsants; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Epilep | 2009 |
The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
Topics: Anticonvulsants; Congenital Abnormalities; Delayed-Action Preparations; Drug Design; Epilepsy, Gener | 2009 |
Piracetam for fetal distress in labour.
Topics: Apgar Score; Cesarean Section; Delivery, Obstetric; Female; Fetal Distress; Humans; Labor, Obstetric | 2012 |
Levetiracetam safety profiles and tolerability in epilepsy patients.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Animals; Anticonvulsants; Astheni | 2004 |
The safety of levetiracetam.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Blood Cells; Body Weight; Child; Child Behavior; Drug Hype | 2007 |
Piracetam for fetal distress in labour.
Topics: Delivery, Obstetric; Female; Fetal Distress; Humans; Labor, Obstetric; Neuroprotective Agents; Pirac | 2000 |
Pharmacokinetic considerations in prescribing antiepileptic drugs.
Topics: Adult; Age Factors; Aged; Anticonvulsants; Biological Availability; Child; Drug Interactions; Drug P | 2001 |
Safety profile of levetiracetam.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Central Nervous System Diseases; Controlled Clinical T | 2001 |
Piracetam for fetal distress in labour.
Topics: Delivery, Obstetric; Female; Fetal Distress; Humans; Labor, Obstetric; Neuroprotective Agents; Pirac | 2002 |
Chemical manipulation of some aspects of aging.
Topics: Aging; Animals; Ergolines; Estrus; Female; Humans; Longevity; Male; Monoamine Oxidase Inhibitors; Pi | 1978 |
2 trials available for piracetam and Pregnancy
| Article | Year |
|---|---|
Results obtained with piracetam in foetal distress during labour.
Topics: Amniotic Fluid; Apgar Score; Birth Weight; Clinical Trials as Topic; Female; Fetal Blood; Fetal Dist | 1983 |
[The protective effect of piracetam during delivery].
Topics: Adult; Electroencephalography; Female; Fetal Hypoxia; Fetal Monitoring; Humans; Hypoxia, Brain; Infa | 1979 |
52 other studies available for piracetam and Pregnancy
| Article | Year |
|---|---|
Seizure Deterioration with Increased Levetiracetam Blood Concentration during the Postpartum Period in Refractory Temporal Lobe Epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy, Temporal Lobe; Female; Humans; Levetiracetam; Piracetam; Postpartu | 2022 |
Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Piracetam; Pregnancy; Pregnant Women; Retr | 2023 |
Treatment with lacosamide impedes generalized seizures in a rodent model of cortical dysplasia.
Topics: Acetamides; Animals; Anticonvulsants; Electroencephalography; Female; GABA Antagonists; Lacosamide; | 2017 |
Teratogenic potential of antiepileptic drugs in the zebrafish model.
Topics: Acetamides; Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Ethosuximide; Female; F | 2013 |
Antiepileptic drugs and neurocognitive development.
Topics: Anticonvulsants; Child Development; Female; Humans; Language Development; Levetiracetam; Male; Pirac | 2014 |
In utero exposure to levetiracetam vs valproate: development and language at 3 years of age.
Topics: Adult; Anticonvulsants; Child Development; Child, Preschool; Epilepsy; Female; Humans; Language Deve | 2014 |
Increased levetiracetam clearance associated with a breakthrough seizure in a pregnant patient receiving once/day extended-release levetiracetam.
Topics: Adolescent; Anticonvulsants; Delayed-Action Preparations; Female; Humans; Infant, Newborn; Levetirac | 2014 |
The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy.
Topics: Anticonvulsants; Female; Fructose; Humans; Lamotrigine; Levetiracetam; Piracetam; Pregnancy; Registr | 2014 |
The teratogenicity of the newer antiepileptic drugs - an update.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Fetus; Fructose; Humans; Lamo | 2014 |
Increased levetiracetam clearance and breakthrough seizure in a pregnant patient successfully handled by intensive therapeutic drug monitoring.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Levetirac | 2015 |
Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy.
Topics: Acetamides; Adult; Anticonvulsants; Female; Fetal Blood; Humans; Infant, Newborn; Lacosamide; Leveti | 2015 |
[Position Statement of Hungarian Epilepsy League: The use of valproate preparations for epilepsy in pregnancy and in women of childbearing age].
Topics: Adolescent; Adult; Anticonvulsants; Cognition; Contraception; Dose-Response Relationship, Drug; Drug | 2015 |
Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice.
Topics: Amino Acid Transport System y+; Animals; Astrocytes; Cells, Cultured; Drug Delivery Systems; Female; | 2016 |
Evaluation of apoptotic cell death on liver and kidney tissues following administration of levetiracetam during prenatal period.
Topics: Animals; Animals, Newborn; Anticonvulsants; Apoptosis; Chi-Square Distribution; DNA Nucleotidylexotr | 2017 |
Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Longitu | 2018 |
Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate.
Topics: Adult; Anticonvulsants; Child; Cognition Disorders; Cross-Sectional Studies; Epilepsy; Female; Follo | 2016 |
Impending status epilepticus and anxiety in a pregnant woman treated with levetiracetam.
Topics: Administration, Oral; Adult; Anticonvulsants; Anxiety; Epilepsy, Frontal Lobe; Fear; Female; Humans; | 2008 |
Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Lamotrigine; Levetiracetam; Mat | 2009 |
Effect of prenatal levetiracetam exposure on motor and cognitive functions of rat offspring.
Topics: Animals; Anticonvulsants; Avoidance Learning; Cognition; Exploratory Behavior; Female; Learning; Lev | 2010 |
Effects of levetiracetam on blood-brain barrier disturbances following hyperthermia-induced seizures in rats with cortical dysplasia.
Topics: Animals; Anticonvulsants; Blood-Brain Barrier; Disease Models, Animal; Female; Fever; Fluorescein; G | 2010 |
Child development following in utero exposure: levetiracetam vs sodium valproate.
Topics: Anticonvulsants; Child Development; Child, Preschool; Cognition; Epilepsy; Female; Humans; Infant; L | 2011 |
Carbamazepine in pregnancy: Levetiracetam and lamotrigine are better options.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Contraindications; Epilepsy; Female; Hu | 2011 |
No effect of oral contraceptives on the metabolism of levetiracetam.
Topics: Adolescent; Adult; Anticonvulsants; Contraceptives, Oral; Dose-Response Relationship, Drug; Epilepsy | 2011 |
Postpartum cerebral venous thrombosis.
Topics: Anticoagulants; Anticonvulsants; Brain; Female; Heparin; Humans; Hypertension; Levetiracetam; Magnes | 2011 |
Pregnancy complicated by recurrent brain abscess after extraction of an infected tooth.
Topics: Adult; Anti-Bacterial Agents; Anticonvulsants; Brain Abscess; Cefotaxime; Cesarean Section; Dexameth | 2011 |
Teratogenicity of the newer antiepileptic drugs--the Australian experience.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Administration Schedule; Female; Fruct | 2012 |
Sensitivity of computed tomography angiography vs catheter angiography in the detection of a ruptured intracranial infectious aneurysm in a pregnant woman.
Topics: Adult; Aneurysm, Infected; Aneurysm, Ruptured; Anti-Bacterial Agents; Anticonvulsants; Brain; Cathet | 2012 |
Increased levetiracetam clearance in pregnancy: is seizure frequency affected?
Topics: Anticonvulsants; Female; Humans; Levetiracetam; Piracetam; Pregnancy; Pregnancy Complications; Seizu | 2012 |
[Clinical application of newer anti-epileptic drugs].
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructose; Gabapentin; gamma- | 2012 |
Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy, Generalize | 2013 |
Levetiracetam monotherapy during pregnancy: a case series.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Levetiracet | 2003 |
Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity.
Topics: Animals; Butyrates; Disease Models, Animal; Female; Fetus; Levetiracetam; Mice; Piracetam; Pregnancy | 2003 |
Levetiracetam concentrations in serum and in breast milk at birth and during lactation.
Topics: Anticonvulsants; Breast Feeding; Epilepsy; Female; Fetal Blood; Humans; Infant, Newborn; Lactation; | 2005 |
Levetiracetam pharmacokinetics in neonates at birth.
Topics: Amniotic Fluid; Anticonvulsants; Epilepsy, Complex Partial; Female; Fetal Blood; Half-Life; Humans; | 2006 |
Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Body Weight; Epilepsy; Female; Humans; Infant, | 2006 |
Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation.
Topics: Anticonvulsants; Breast Feeding; Delivery, Obstetric; Epilepsy; Female; Fetal Blood; Half-Life; Huma | 2007 |
Antiepileptic drugs and brain maturation: fetal exposure to lamotrigine generates cortical malformations in rats.
Topics: Animals; Anticonvulsants; Brain; Cell Count; Cell Movement; Dose-Response Relationship, Drug; Female | 2008 |
Serum concentration/dose ratio of levetiracetam before, during and after pregnancy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Piracetam; Pregnancy; Retrospective | 2008 |
Contraindications to phenytoin in emergency department patients with seizures.
Topics: Anticonvulsants; Contraindications; Emergency Service, Hospital; Epilepsy; Female; Humans; Levetirac | 2009 |
Effect of some drugs, experimental stress and estrus on unstable and fixed conditioned alimentary motor reflexes in cats. Part II.
Topics: Amphetamine; Animals; Barbiturates; Caffeine; Cats; Chlorprothixene; Conditioning, Classical; Diazep | 1983 |
Effect of some drugs, experimental stress and estrus on unstable and fixed conditioned alimentary motor reflexes in cats.
Topics: Amphetamine; Animals; Barbiturates; Behavior, Animal; Caffeine; Cats; Chlorprothixene; Conditioning, | 1982 |
Effects of piracetam on brain development in newborn rats exposed to hypoxia.
Topics: Animals; Animals, Newborn; Brain; Brain Chemistry; Corpus Striatum; Dopamine; Female; Hypoxia; Pirac | 1984 |
[Effect of nootropic agents on serum biochemical indices in intellectually deficient children].
Topics: Cerebral Cortex; Child; Female; Fetal Hypoxia; Humans; Hypoxia, Brain; Intellectual Disability; Isoe | 1983 |
Alterations of the fetal EEG under the influence of labour, hypoxia and analgetics.
Topics: Analgesics; Brain; Electroencephalography; Female; Fetus; Humans; Hypoxia; Labor, Obstetric; Piracet | 1981 |
Action of piracetam in childbirth.
Topics: Adolescent; Adult; Child; Female; Fetal Distress; Fetal Membranes, Premature Rupture; Fetus; Humans; | 1980 |
[Behavior disorders in rats exposed to intrauterine hypoxia, and their correction by postnatal treatment with piracetam].
Topics: Animals; Behavior, Animal; Female; Fetal Hypoxia; Learning Disabilities; Memory Disorders; Piracetam | 1993 |
[Piracetam as a corrector of long-term learning disorders caused by prenatal alcohol exposure: the significance of the length of therapy].
Topics: Animals; Avoidance Learning; Ethanol; Female; Learning Disabilities; Male; Nootropic Agents; Piracet | 1996 |
[Damage to plastic properties of synaptic transmission in the rat hippocampus resulting from prenatal hypoxia, and their normalization by treatment with nootropic dipeptides].
Topics: Animals; Dipeptides; Female; Hippocampus; Hypoxia; Male; Neuronal Plasticity; Nootropic Agents; Pira | 1995 |
Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance?
Topics: Alcohol-Induced Disorders, Nervous System; Animals; Disease Models, Animal; Female; Learning Disabil | 2001 |
[Pharmacokinetic of piracetam during labour influence to acid-base-status in maternal and fetal blood (author's transl)].
Topics: Acid-Base Equilibrium; Female; Fetal Blood; Fetal Heart; Half-Life; Humans; Hydrogen-Ion Concentrati | 1977 |
[Pharmacokinetics of piracetam during delivery].
Topics: Amniotic Fluid; Delivery, Obstetric; Female; Fetal Blood; Half-Life; Humans; Infant, Newborn; Matern | 1978 |
Effects of nootropic drugs on some behavioural and biochemical changes after early postnatal hypoxia in the rat.
Topics: Animals; Body Weight; Corpus Striatum; Deanol; Dopamine; Ethanolamines; Female; Hypoxia; In Vitro Te | 1986 |